In our tenth Transforming Cardiac Care webinar, clinical researcher Sarah Bär, MD, PhD, from Turku, Finland, explores cutting-edge findings about how the evaluation of coronary plaque with AI can reveal heart attack risk. Attendees will learn how advanced plaque analysis using machine learning algorithms compares to traditional methods of assessing cardiac health. See how tests that only measure calcified plaque, like Coronary Artery Calcium scoring, provide an incomplete view of cardiovascular risk—and see how a more comprehensive approach can better assess plaque burden. Dr. Bär’s presentation will conclude with a Q&A session, open to all attendees.
OUR KEY PANELISTS
Sarah Bär, MD, PhD
Turku PET Centre, Turku University Hospital, Turku, Finland
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
July 31, 2024
Track Your Plaque: Identifying Residual Risk After Coronary Artery Disease Treatment
In our ninth Transforming Cardiac Care webinar, preventive cardiologist John Osborne, MD, PhD, FACC, FNLA, guides viewers through research and real-world examples illustrating how plaque subtypes relate to coronary artery disease advancement. Learn how to identify those with disease progression, even after undergoing medical therapy and risk factor reduction. See how coronary computed tomography angiography (CTA) can aid in understanding plaque phenotyping and measurements of volume, stenoses, and ischemia. Dr. Osborne’s presentation concludes with a Q&A session.
OUR KEY PANELISTS
John Osborne, MD, PhD, FACC, FNLA
Founder & Director, State of the Heart Cardiology
CEO, Metroplex Cardiology
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
March 19, 2024
The TRANSFORM Clinical Trial: Measuring the Prevention Potential of AI-Enabled Coronary CTA Analysis and Disease Staging
In our eighth Transforming Cardiac Care webinar, we discuss the upcoming, landmark TRANSFORM randomized controlled trial that uses Cleerly’s AI-powered CCTA analysis. The study chair, Dr. Deepak L. Bhatt of Mount Sinai Fuster Heart Hospital, joins Cleerly’s clinical leaders to discuss and answer questions about the study’s goal of demonstrating that a highly personalized care strategy, empowered by AI identification of a patient’s coronary artery disease (CAD) stage, can outperform traditional risk factor management and even prevent cardiovascular events.
OUR KEY PANELISTS
Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAI
Director, Mount Sinai Fuster Heart Hospital
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
Udo Hoffmann, MD, MPH
Chief Scientific Officer,
Cleerly Inc.
September 21, 2023
The True Measure of Cardiac Risk: How AI-QCT Transforms Heart Disease Diagnosis and Treatment
In our seventh Transforming Cardiac Care webinar, we examined the conventional approaches to evaluating heart disease risk factors, such as cholesterol levels, and their limitations when determining heart health.
OUR KEY PANELISTS
Louis B. Malinow, MD
Director of Education and Clinical Excellence,
MDVIP
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
May 12, 2023
Hope for a New Era in Cardiac Care: How AI-based Cardiac Imaging Compliments Calcium Scoring
In our sixth Transforming Cardiac Care webinar, we compare coronary artery calcium (CAC) scoring with computed tomography angiography (CCTA) enabled by artificial intelligence (AI).
OUR KEY PANELISTS
Arthur Agatston, MD, FACC
CEO and Founder of The Agatston Center for Preventive Medicine
Creator of the Agatston Score
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
February 16, 2023
Perform the Perfect CT Angiogram: Maximize Clinical Utility with AI and Best Practices
Our fifth webinar is a discussion about the emergence of CCTA as a more effective approach to heart attack prevention. When enabled by artificial intelligence, and supported by the right training, equipment, and protocols, non-invasive CCTA offers a level of clinical efficacy that outperforms SPECT and other gold standards currently used to evaluate CAD.
OUR KEY PANELISTS
Marcio Sommer Bittencourt, MD
Associate Professor of Medicine and Radiology,
University of Pittsburgh
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
October 6, 2022
Stress Less: How AI-Enabled CCTA Outperforms Stress Testing for Heart Disease Detection
Join us for our fourth webinar in our Transforming Cardiac Care series for a discussion about new evidence showing that AI-enabled coronary computed tomography angiography (CCTA) has a higher diagnostic accuracy for detecting coronary artery disease (CAD).
OUR KEY PANELISTS
Andrew Choi, MD
Associate Professor of Medicine and Radiology,
George Washington University
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
July 21, 2022
How Heart Disease Evolves with Treatment: A Personalized Approach to Cardiovascular Disease Prevention
Learn how CCTA is used by providers in assessing coronary artery disease to inform individualized treatment.
OUR KEY PANELISTS
Matthew Budoff, MD
Preventive Cardiologist and Professor of Medicine,
David Geffen School of Medicine
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
May 25, 2022
Staging Atherosclerosis: Understanding plaque burden for patient Evaluation and treatment
Learn about the field’s first novel, four-tiered atherosclerotic plaque staging system proposed by Cleerly — the different stages, clinical utility and implementation.
OUR KEY PANELISTS
Andrew Freeman, MD, FACC
Director of Cardiovascular Prevention and Wellness,
National Jewish Health
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.
March 30, 2022
Stenosis vs. Atherosclerosis: What’s the driving force behind increased heart attack risk?
Our panelists discussed a highly promising, clinically proven new standard of heart care and AI-driven digital technology that allows physicians to more accurately measure disease, provide treatment and prevent future heart attacks.
OUR KEY PANELISTS
Daniele Andreini, MD
Assistant Professor of Cardiovascular Disease,
University of Milan
Hosted by Cleerly
James K. Min, MD
Chief Executive Officer,
Cleerly Inc.
James P. Earls, MD
Chief Medical Officer,
Cleerly Inc.